Drug Trial Radar · NCT07680166
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Oct 31, 2029
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- Xentria, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of XTMAB-16 in patients with pulmonary sarcoidosis
Conditions
- Pulmonary Sarcoidosis
Interventions
XTMAB-16Drug
Infusion
PlaceboDrug
Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 24Time frame: Baseline to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.